Please use this identifier to cite or link to this item:
Volltext verfügbar? / Dokumentlieferung
doi:10.22028/D291-38470
Title: | Drug-Coated Balloon for Small Coronary Artery Disease in Patients With and Without High-Bleeding Risk in the BASKET-SMALL 2 Trial |
Author(s): | Scheller, Bruno Rissanen, Tuomas T. Farah, Ahmed Ohlow, Marc-Alexander Mangner, Norman Wöhrle, Jochen Möbius-Winkler, Sven Weilenmann, Daniel Leibundgut, Gregor Cuculi, Florim Gilgen, Nicole Coslovsky, Michael Mahfoud, Felix Jeger, Raban V. |
Language: | English |
Title: | Circulation : Cardiovascular interventions |
Volume: | 15 |
Issue: | 4 |
Pages: | 323-333 |
Publisher/Platform: | American Heart Association |
Year of Publication: | 2022 |
Free key words: | coronary vessels drug-eluting stents mortality percutaneous coronary intervention population |
DDC notations: | 610 Medicine and health |
Publikation type: | Journal Article |
Abstract: | BACKGROUND: Patients at high-bleeding risk (HBR) undergoing percutaneous coronary intervention represent a challenging patient population. The use of drug-coated balloon (DCB) allows shorter duration of dual antiplatelet therapy compared with drug-eluting stents (DES) and reduces thrombotic risk due to the absence of a permanent implant. The present analysis aimed to investigate if the effect of DCB versus DES differed between patients with and without HBR treated with percutaneous coronary intervention in small coronary arteries. METHODS: This prespecified subgroup analysis of a multicenter, randomized, noninferiority trial included 758 patients with de novo lesions in coronary vessels <3 mm and an indication for percutaneous coronary intervention, randomized to DCB (n=382) or second-generation DES (n=376). Patients were followed over 3 years for major adverse cardiac events. RESULTS: Of the 758 patients randomized, 155 (20%) had HBR; these patients had higher mortality at 3 years (hazard ratio [95% CI], 3.09 [1.78–5.36]; P<0.001). Rates of major bleeding events were overall low but tended to be lower after DCB versus DES (1.6% versus 3.7%; P=0.064), were similar in patients with HBR (4.5% versus 3.4%) but less frequent in DCBversus DES-treated patients without HBR (0.9% versus 3.8%). There was no difference in major adverse cardiac events between DCB and DES regardless of bleeding risk (HBR, hazard ratio: 1.16 [0.51–2.62]; P=0.719 versus non-HBR, 0.96 [0.62–1.49]; P=0.863). CONCLUSIONS: DCBs were similarly safe and effective as current-generation DES in the treatment of coronary arteries <3 mm, regardless of bleeding risk. In patients treated with DCB, there was a trend towards a reduction of severe bleeding events at 3 years. |
DOI of the first publication: | 10.1161/CIRCINTERVENTIONS.121.011569 |
URL of the first publication: | http://dx.doi.org/10.1161/CIRCINTERVENTIONS.121.011569 |
Link to this record: | urn:nbn:de:bsz:291--ds-384708 hdl:20.500.11880/34697 http://dx.doi.org/10.22028/D291-38470 |
ISSN: | 1941-7632 1941-7640 |
Date of registration: | 8-Dec-2022 |
Description of the related object: | Supplemental Material |
Related object: | https://www.ahajournals.org/doi/suppl/10.1161/CIRCINTERVENTIONS.121.011569/suppl_file/CircInterventions_CIRCCVINT-2021-011569-T_supp2.pdf |
Faculty: | M - Medizinische Fakultät |
Department: | M - Innere Medizin |
Professorship: | M - Prof. Dr. Michael Böhm M - Prof. Dr. Bruno Scheller-Clever |
Collections: | SciDok - Der Wissenschaftsserver der Universität des Saarlandes |
Files for this record:
There are no files associated with this item.
Items in SciDok are protected by copyright, with all rights reserved, unless otherwise indicated.